Publications

Nature medicine

Publisher Correction: Clinical development of cancer vaccines.

01-04-2026

Nature medicine

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

01-03-2026

Transplantation and cellular therapy

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles.

26-02-2026

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

01-10-2025

Nature medicine

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

01-09-2025

Med (New York, N.Y.)

Advances in TIL therapy: Expanding the horizons beyond melanoma.

08-08-2025

British journal of cancer

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

01-06-2025

Medical decision making : an international journal of the Society for Medical Decision Making

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

01-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

01-04-2025

The oncologist

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

10-03-2025

ESMO open

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

01-03-2025

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

01-02-2025

Frontiers in immunology

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.

24-12-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

Cancers

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

26-07-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

01-06-2024

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Med (New York, N.Y.)

Melanoma neoantigen vaccines: Are we getting more personal now?

12-04-2024

Oncology research and treatment

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

08-04-2024

The Lancet regional health. Europe

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.

01-04-2024

Nature reviews. Clinical oncology

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Nature communications

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

23-02-2024

ESMO open

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

01-02-2024

Clinical nuclear medicine

The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

01-02-2024

Journal for immunotherapy of cancer

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

01-07-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

European journal of cancer (Oxford, England : 1990)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

01-06-2023

Cancers

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

26-05-2023

Critical reviews in oncology/hematology

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.

01-03-2023

Cancer treatment reviews

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

01-02-2023

Cancers

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

07-01-2023

Melanoma research

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

01-12-2022

JCO oncology practice

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.

01-10-2022

The Lancet. Oncology

Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.

01-10-2022

The Lancet. Oncology

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.

01-07-2022

Cell reports. Medicine

TIL classified to memory state are correlated with response to immune checkpoint blockade.

21-06-2022

European urology oncology

Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination Therapy.

01-06-2022

Nature reviews. Clinical oncology

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.

01-06-2022

International journal of cancer

The unfavorable effects of COVID-19 on Dutch advanced melanoma care.

01-03-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.

01-02-2022

International journal of cancer

Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.

15-01-2022

European journal of cancer (Oxford, England : 1990)

Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.

01-01-2022

Cell reports

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8⁺ T cells.

16-11-2021